Patent victory reignites rumors of BMS takeover

Following yesterday's announcement by Sanofi-Aventis and Bristol-Myers Squibb that they had successfully defended their patent on the blood thinner Plavix, the analysts quickly revived speculation that the French pharma company could revive an effort to buy BMS. Internal dissension at Sanofi, though, coupled with a high valuation for Bristol-Myers Squibb is giving the analysts some pause, however.

- see this release for more on the patent
- read the Financial Times report

Related Articles:
More details emerge on secret Plavix pact. Report
Rumor Mill: Is BMS going on the sales block? Report
Analysts buzzing about possible Bristol-Myers sale. Report
Sanofi says no charges on Plavix. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.